Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 58-year-old allogeneic stem cell transplant recipient developed dizziness during chemotherapy for systemic post-transplant lymphoproliferative disorder. Brain magnetic resonance imaging (MRI) revealed multiple lesions on fluid-attenuated inversion recovery images; however, they lacked gadolinium contrast enhancement. Under the assumption of central nervous system post-transplant lymphoproliferative disorder (PTLD), we treated the patient with high-dose methotrexate without success. The absence of contrast enhancement on MRI and unresponsiveness to chemotherapy led us to suspect progressive multifocal leukoencephalopathy (PML). The presence of John Cunningham virus DNA in the cerebrospinal fluid led to a definitive diagnosis. Therefore, clinicians encountering patients with enhancement-lacking brain lesions during PTLD should consider PML.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.5503-25 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Asynchronous Development of B-cell and T-cell Post-transplant Lymphoproliferative Disorder in a Pediatric Heart Transplant Patient.
J Pediatr Hematol Oncol
September 2025
Division of Pediatric Hematology-Oncology, Mayo Clinic Children's, Rochester, MN.
Post-transplant lymphoproliferative disorder is a rare and serious complication of organ and stem cell transplant secondary to immunosuppressive therapies, most commonly of monomorphic B-cell subtype. Here we describe the first reported case of a pediatric heart transplant patient who developed both monomorphic B-cell and nondestructive PTLD with plasmacytic hyperplasia followed by an unrelated case of monomorphic T-cell and nondestructive PTLD with plasmacytic hyperplasia, which later relapsed. We detail the patient's risk factors for development of PTLD and her successful treatment regimens.
View Article and Find Full Text PDFLoss-Prone HLA Class I Alleles Inform Outcomes of Early Hematopoietic Cell Transplantation in Acquired Aplastic Anemia.
Am J Hematol
September 2025
Department of Hematology, Tohoku University Hospital, Sendai, Japan.
HLA class I allele loss in acquired aplastic anemia (AA) represents an immune escape from the T cell-mediated pathogenesis. We investigated the impact of loss-prone HLA alleles on the hematopoietic cell transplantation (HCT) outcomes using registry data of 875 Japanese patients with acquired AA. HLA associations were evident exclusively among 399 patients who received HCT within 1 year of the diagnosis, consistent with the predominance of HLA loss in this group.
View Article and Find Full Text PDFIncidence, screening, and management of malignancies in liver transplant patients: A review.
World J Transplant
September 2025
Division of Gastroenterology, Tristar Centennial Medical Center, Nashville, TN 37203, United States.
Liver transplantation (LT) is the definitive treatment for end-stage liver disease, acute liver failure, and liver cancer. Although advancements in surgical techniques, postoperative care, and immunosuppressive therapies have significantly improved outcomes, the long-term use of immunosuppression has increased the risk of complications, including infections, cardiovascular disease, and cancer. Among these, malignancies (DNMs) are a major concern, accounting for 20%-25% of deaths in LT recipients surviving beyond the early post-transplant period.
View Article and Find Full Text PDFMalignancies After Renal Transplantation: Frequency, Etiology, and Prognosis-A Single Center Experience.
J Clin Med
August 2025
Department of Internal Medicine, Faculty of Medicine, Istanbul University, 34452 Istanbul, Türkiye.
: Renal transplant recipients face significant long-term graft and patient loss due to post-transplant malignancies. This study aimed to characterize post-transplant malignancies, determine mortality risk factors, and evaluate patient outcomes. : This retrospective study included 2052 kidney transplant recipients who underwent transplantation between 1976 and 2019 at our institution, other national centers, or international facilities, and who had at least six months of follow-up.
View Article and Find Full Text PDFThe interplay between Epstein-Barr Virus and Cytomegalovirus reactivation following allogeneic hematopoietic cell transplantation in the era of primary CMV prophylaxis.
Clin Microbiol Infect
August 2025
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Objectives: Epstein-Barr virus (EBV) reactivation following allogeneic hematopoietic cell transplantation (allo-HCT) is associated with increased mortality and possible post-transplant lymphoproliferative disorder (PTLD). With the lack of prophylactic agents, identifying modifiable risk factors to prevent EBV-related mortality is desired. Cytomegalovirus (CMV) DNAemia has been previously associated with EBV DNAemia; the impact of letermovir prophylaxis on this association remains unclear.
View Article and Find Full Text PDF